Page last updated: 2024-08-22

cladribine and Acute Relapsing Multiple Sclerosis

cladribine has been researched along with Acute Relapsing Multiple Sclerosis in 158 studies

Research

Studies (158)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	9 (5.70)	29.6817
2010's	48 (30.38)	24.3611
2020's	101 (63.92)	2.80

Authors

Authors	Studies
Avxentyev, NA; Davydovskaya, MV; Frolov, MY; Klabukova, DL; Makarova, YV	1
Adamec, I; Habek, M; Jovanović, I; Krbot Skorić, M	1
Fenwick, E; Harty, GT; Kroep, S; Piena, MA; Simons, C; van Hout, BA; Wong, SL	1
Baker, D; Dobson, R; Giovannoni, G; Kang, AS; MacDougall, A; Schmierer, K	1
Brescia Morra, V; Carotenuto, A; Disanto, G; Gobbi, C; Moccia, M; Sacco, R; Spiezia, AL; Zecca, C	1
Alexandri, N; Brochet, B; Havrdova, EK; Hupperts, R; Keller, B; Langdon, D; Lechner-Scott, J; Montalban, X; Nolting, A; Patti, F; Piehl, F; Rejdak, K; Selmaj, K; Solari, A; Valis, M	1
Alexandri, N; Giovannoni, G; Ponzano, M; Signori, A; Sormani, MP	1
Bagatto, D; Battezzi, A; Deana, C; Lorenzut, S; Pecori, D; Tuniz, F	1
Aydemir, A; Bezemer, I; Butzkueven, H; Korhonen, P; Moore, N; Sabidó, M; Sõnajalg, J	1
Papazisis, G; Stamatellos, VP	1
Moser, T; Sellner, J; Ziemssen, T	1
Celius, EG; Høgestøl, EA; Myhr, KM; Nygaard, GO; Skattebøl, L; Sowa, P; Torgauten, H; Torkildsen, Ø	1
Atula, S; Järvinen, E; Kuusisto, H; Rauma, I; Ryytty, M; Sipilä, JOT; Soilu-Hänninen, M; Viitala, M	1
Burman, J; Bø, L; Kvistad, SAS; Lehmann, AK; Melve, GK; Tolf, A; Torkildsen, Ø; Zjukovskaja, C	1
Basu, S; Ben-Amor, AF; Girard, P; Munafo, A; Roy, S; Terranova, N	1
Chandran, S; Connick, P; Foley, P; Glasmacher, SA; Hassan, Z; Kearns, PK; Reetz, K; Tauber, S	1
Al-Harbi, T; Alroughani, R; Ampapa, R; Barnett, M; Bergamaschi, R; Bovis, F; Boz, C; Butler, E; Butzkueven, H; Buzzard, K; Cartechini, E; Castillo-Triviño, T; Cristiano, E; Csepany, T; de Gans, K; Dominguez, JA; Duquette, P; Eichau, S; Ferraro, D; Fragoso, Y; Gerlach, O; Girard, M; Gouider, R; Grammond, P; Grand'Maison, F; Granella, F; Gray, O; Havrdova, EK; Hodgkinson, S; Horakova, D; Hughes, S; Iuliano, G; Izquierdo, G; Kalincik, T; Kappos, L; Kermode, A; Lechner-Scott, J; Lugaresi, A; Macdonell, R; Malpas, C; McCombe, P; Moore, F; Onofrj, M; Ozakbas, S; Petersen, T; Prat, A; Prevost, J; Rozsa, C; Saladino, ML; Sanchez-Menoyo, JL; Sempere, AP; Sharmin, S; Shaw, C; Shaygannejad, V; Shuey, N; Sidhom, Y; Simo, M; Singhal, B; Sirbu, CA; Skibina, O; Slee, M; Sola, P; Solaro, C; Sormani, MP; Soysal, A; Spitaleri, D; Taylor, B; Terzi, M; Trojano, M; Turkoglu, R; van der Walt, A; van Pesch, V; Van Wijmeersch, B; Vucic, S; Yamout, B	1
Afanasiev, S; Brill, L; Haham, N; Levin, N; Rechtman, A; Rozenberg, A; Shifrin, A; Vaknin-Dembinsky, A; Zveik, O	1
Boschert, U; Centonze, D; Chudecka, A; Oreja-Guevara, C; Roy, S; Schmierer, K; Wiendl, H	2
Aslan, D; Hackert, J; Hagenacker, T; Huntemann, N; Kleinschnitz, C; Kleinschnitz, K; Meuth, SG; Pawlitzki, M; Pfeuffer, S; Pul, R; Rolfes, L; Ruck, T; Schmidt, M; Skuljec, J; Su, C	1
Holko, P; Kawalec, P; Osiecka, O; Śladowska, K	1
Butler, E; Butzkueven, H; Buzzard, K; Eichau, S; Girard, M; Hodgkinson, S; Jokubaitis, V; Kalincik, T; Lechner-Scott, J; Monif, M; Oh, J; Prevost, J; Skibina, O; van der Walt, A; Van Pesch, V; Zhong, M	1
Boyko, AN	1
Damian, D; Dangond, F; Galazka, A; Harty, G; Jack, D; Vermersch, P; Wong, SL	2
Bayas, A; Kallmann, B; Kleinschnitz, C; Linker, R; Mäurer, M; Meuth, SG; Rieckmann, P; Wattjes, MP	1
Comi, G; Dangond, F; Giovannoni, G; Jack, D; Rammohan, K; Rieckmann, P; Vermersch, P	1
Alexandri, N; Coyle, PK; Dangond, F; Galazka, A; Giovannoni, G; Leist, TP; Rammohan, K; Sormani, MP; Stefano, N	1
Andone, S; Balasa, R; Hutanu, A; Maier, S; Manu, D; Oiaga, M; Voidazan, S	1
Fleifel, L; Khamis, C; Koussa, S; Matni, M; Mohamed, O; Sharifi, S; Yamout, B	1
Achiron, A; Didikin, M; Dreyer-Alster, S; Flechter, S; Harari, G; Magalashvili, D; Mandel, M	1
Alexandri, N; Battaglini, M; Cortese, R; De Stefano, N; Gentile, G; Inderyas, M; Luchetti, L; Sormani, MP	1
Brownlee, WJ	1
Haug, U; Kollhorst, B; Platzbecker, K; Wentzell, N	1
Alroughani, R; Barnett, M; Boz, C; Butzkueven, H; Hodgkinson, S; Horakova, D; Izquierdo, G; Jokubaitis, V; Kalincik, T; Karabudak, R; Khoury, SJ; Kubala Havrdova, E; Kuhle, J; Lechner-Scott, J; Macdonell, R; Merlo, D; Monif, M; Onofrj, M; Ozakbas, S; Patti, F; Prat, A; Prevost, J; Roos, I; Skibina, O; Slee, M; van der Walt, A; Van Pesch, V; Zhou, Z; Zhu, C	1
Ciplea, AI; Dost-Kovalsky, K; Gold, R; Hellwig, K; Thiel, S	1
Homa, M; Kaczor, MP; Kaczyński, Ł; Paczwa, P; Piasecka-Stryczyńska, K; Rejdak, K; Rolka, M; Staśkiewicz, W; Wójcik, R	1
Al-Asmi, A; Alroughani, R; Altintas, A; Ampapa, R; Blanco Morgado, Y; Butzkueven, H; Gerlach, O; Hodgkinson, S; Horakova, D; Kalincik, T; Kuhle, J; Laureys, G; Lechner-Scott, J; Macdonell, R; Oh, J; Ozakbas, S; Patti, F; Sanchez-Menoyo, JL; Soysal, A; Spelman, T; Spitaleri, D; Terzi, M; Tundia, N; Van Der Walt, A; van Pesch, V; Wong, SL; Yamout, B	1
Assefi, A; D'Eramo, M; Etchepare, A; Grinspan, A; Iut, VC; Negrotto, L	1
Heick, A; Joensen, H; Magyari, M; Pihl, CE; Pontieri, L; Rasmussen, PV; Ratzer, R; Schäfer, J; Sellebjerg, F; Sorensen, PS	1
Ginestal, R; Los Santos, H; Morán, OD; Ordoñez, C; Rubio-Rodríguez, D; Rubio-Terrés, C; Sánchez-Magro, I	1
Apóstolos-Pereira, SL; Callegaro, D; Mahler, JV; Nascimento, RFV; Pipek, LZ; Silva, GD	1
Aydemir, A; Borsi, L; Boyko, A; Correale, J; Edan, G; Freedman, MS; Giovannoni, G; Leist, T; Montalban, X; Rammohan, K; Stefoski, D; Verdun di Cantogno, E; Yamout, B	1
Ferrè, L; Filippi, M; Martinelli, V; Meani, A; Moiola, L; Rocca, MA; Zanetta, C	1
Afrashteh, F; Mirmosayyeb, O; Mohamadi, M; Nabizadeh, F; Najdaghi, S; Rahmani, S; Rajabi, R	1
Aerts, S; Khan, H; Peeters, LM; Popescu, V; Severijns, D; Van Wijmeersch, B	1
Boschert, U; Cerra, J; Giovannoni, G; Kalatskaya, I; Leist, T; Rolfe, PA	1
Budimkic, MS; Drulovic, J; Ivanovic, J; Mesaros, S; Momcilovic, N	1
Al-Asmi, A; Alroughani, R; Altintas, A; Ampapa, R; Butzkueven, H; Der Walt, AV; Gerlach, O; Hodgkinson, S; Horakova, D; Kalincik, T; Kuhle, J; Laureys, G; Lechner-Scott, J; Macdonell, R; Morgado, YB; Oh, J; Ozakbas, S; Patti, F; Pesch, VV; Sanchez-Menoyo, JL; Soysal, A; Spelman, T; Spitaleri, D; Terzi, M; Tundia, N; Wong, SL; Yamout, B	1
Brownlee, WJ; Duncan, J; Haghikia, A; Harty, GT; Hayward, B; Kayaniyil, S; Khan, Z; Millar, S; Waser, N	1
Ahmed, SF; Al-Hashel, J; AlMojel, M; Alroughani, R	1
Adamczyk-Sowa, M; Bartosik-Psujek, H; Chorąży, M; Jamróz-Wiśniewska, A; Kurkowska-Jastrzębska, I; Kułakowska, A; Piasecka-Stryczyńska, K; Pogoda-Wesołowska, A; Puz, P; Rejdak, K; Stępień, A; Słowik, A; Tokarz-Kupczyk, E	1
Bergmann, W; Boxberger, N; Dudesek, A; Engelmann, R; Fitzner, B; Hecker, M; Koczan, D; Ludwig-Portugall, I; Meister, S; Müller, M; Putscher, E; Schwartz, M; Winkelmann, A; Zettl, UK	1
Abičić, A; Adamec, I; Barun, B; Bašić Kes, V; Brecl Jakob, G; Cindrić, I; Drulović, J; Gabelić, T; Gomezelj, S; Gržinčić, T; Habek, M; Klivényi, P; Krbot Skorić, M; Lazibat, I; Mesaroš, Š; Pekmezović, T; Radulović, L; Rajda, C; Rimac, J	1
Boyko, AN; Dolgushin, MB; Karalkina, MA	1
Alonso, R; Burgos, M; Cabrera, M; Carnero Contentti, E; Casas, M; Cohen, L; Cristiano, E; Deri, N; Garcea, O; Hryb, J; Knorre, E; Lazaro, L; Leguizamon, F; Liguori, NF; Liwacki, S; Luetic, G; Mainella, C; Martinez, A; Menichini, M; Miguez, J; Nofal, P; Pablo, L; Pappolla, A; Patrucco, L; Pestchanker, C; Piedrabuena, R; Pita, C; Rojas, JI; Silva, B; Tizio, S; Tkachuk, V; Vrech, C; Zanga, G	1
Amin, A; Ashton, L; Brownlee, W; Herbert, A	1
Edan, G; Le Page, E	1
Müller, B; Rau, D; Übler, S	1
Song, Y; Sundar, M; Tundia, N; Wang, Y; Wong, SL; Yang, D	1
Alexandri, N; Brieva, L; Brochet, B; Hupperts, R; Keller, B; Kubala Havrdova, E; Langdon, D; Lechner-Scott, J; Maida, EM; Montalban, X; Nolting, A; Patti, F; Piehl, F; Selmaj, K; Smyk, A; Solari, A	1
Budhia, S; de Fransesco, M; Harty, G; Hengstman, GJD; Krol, M; Mahajan, K; Michels, RE; Schiffers, KMH	1
Bell Gorrod, H; Damian, D; Harty, GT; Hettle, R; Latimer, NR; Wong, SL	1
Järvinen, E; Lundström, T; Mankinen, P; Niskala, U; Ruutiainen, J; Soini, E; Sumelahti, ML	1
Costa, J; Guerreiro, R; Miguel, LS; Pinheiro, B	1
Benninger, D; Diserens, K; Hirt, L; Kuntzer, T; Michel, P; Novy, J; Pantazou, V; Pasquier, RD; Perrenoud, M; Rossetti, AO; Rouaud, O; Ryvlin, P; Theaudin, M	1
Caire-Herrera, LE; Casallas-Vanegas, A; Coss-Rovirosa, F; Flores-Rivera, J; Gómez-Figueroa, E; Salado-Burbano, J	1
de Bekker-Grob, EW; Donkers, B; Goossens, LMA; Harty, G; Hoefman, RJ; Jabbarian, LJ; Jonker, MF; Versteegh, MM; Wong, SL	1
Aruta, F; Costa, C; Iodice, R; Iovino, A; Manganelli, F	1
Alfieri, G; Annunziata, M; Cerillo, I; Florio, C; Guarcello, G; Improta, G; Iorio, WD; Maniscalco, GT; Ranieri, A; Renna, R	1
Baker, T; Ciplea, AI; Datta, P; Gold, R; Hale, TW; Hellwig, K; Rewers-Felkins, K	1
Barnett, MH; Butler, E; Butzkueven, H; Fabris, J; Hodgkinson, S; Jack, D; Kalincik, T; Lechner-Scott, J; Lizak, N; McCombe, PA; Parratt, J; Shaw, C; Shuey, N; Skibina, O; Slee, M; Vucic, S	1
Chavan, A; Harty, G; Moller, J; Tafazzoli, A; Wong, SL	1
Bayas, A; Kallmann, B; Kleinschnitz, C; Linker, R; Mäurer, M; Meuth, SG; Rieckmann, P	1
Berger, B; Dersch, R; Engelhardt, M; Fähndrich, S; Rauer, S; Wehrum, T	1
Annovazzi, P; Barcella, V; Baroncini, D; Barone, S; Barrilà, C; Binello, E; Bonavita, S; Cerqua, R; Clerici, VT; Clerico, M; Cocco, E; Cordioli, C; Di Sapio, A; Esposito, S; Fenu, G; Frau, J; Frigeni, B; Grasso, R; Ippolito, D; La Gioia, S; Landi, D; Lanzillo, R; Laroni, A; Lavorgna, L; Maniscalco, GT; Mataluni, G; Pareja-Gutierrez, L; Perini, P; Pontecorvo, S; Rasia, S; Repice, AM; Russo, CV; Saccà, F; Sartori, A; Signori, A; Signoriello, E; Sormani, MP; Stromillo, ML; Visconti, A; Zarbo, IR	1
Brescia Morra, V; De Angelis, M; Lanzillo, R; Moccia, M; Petracca, M	1
Davydovskaya, MV; Kurguzova, DO; Luchinina, EV; Serebrova, SY; Shelekhova, TV; Zhuravleva, MV	1
Boffa, G; Bonavita, S; Cellerino, M; Ferrero, M; Inglese, M	1
Filippi, M; Moiola, L; Nozzolillo, A; Preziosa, P; Rocca, MA	1
Coyle, PK; Dangond, F; Galazka, A; Grosso, M; Leist, TP; Rammohan, K; Sylvester, E	1
Comi, G; Cook, S; Damian, D; Galazka, A; Giovannoni, G; Leist, T; Montalban, X; Nolting, A; Syed, S	1
Ahmad, B; Gummi, R; Walsh, RD	1
Harrer, A; Moser, T; Pilz, G; Radlberger, RF; Sakic, I; Wipfler, P	1
Bartosik-Psujek, H; Górecka, M; Kaczor, M; Kaczyński, Ł; Rolka, M; Wójcik, R; Zięba, P	1
Bass, AD; Fox, EJ; Harlow, DE; Hayward, B; Katz, J; Lebson, LA; Miravalle, AA; Robertson, D; Sloane, JA	1
Adlard, N; Cameron, C; Drudge, C; Häring, DA; Klotz, L; Samjoo, IA; Stoneman, D; Worthington, E; Zhao, M	1
Gold, R; Hoffmann, O	1
Abbadessa, G; Avolio, C; Barone, S; Bonavita, S; Buccafusca, M; Callari, G; Capuano, R; Curti, E; D'Amico, E; Di Francescantonio, V; Ferraro, D; Gallo, A; Granella, F; Lanzillo, R; Lucchini, M; Lus, G; Mirabella, M; Patti, F; Petracca, M; Pontillo, G; Signoriello, E; Sola, P; Valentino, P; Zanghì, A	1
Atkins, HL; Bose, G; Freedman, MS; Rush, C	1
Butzkueven, H; Monif, M; O'Brien, T; Stankovich, J; Voo, VTF	1
Alexandri, N; Coyle, PK; Dangond, F; De Stefano, N; Galazka, A; Giovannoni, G; Keller, B; Leist, T; Rammohan, K; Sormani, MP	1
Hackert, J; Kleinschnitz, C; Kleinschnitz, K; Klotz, L; Meuth, SG; Pfeuffer, S; Pul, R; Rolfes, L; Ruck, T; Wiendl, H	1
Bigaut, K; Cohen, M; de Seze, J; Durand-Dubief, F; Lebrun-Frenay, C; Maillart, E; Planque, E; Zephir, H	1
Eisenberger, U; Fleischer, M; Gäckler, A; Hackert, J; Hagenacker, T; Kleinschnitz, C; Krämer, J; Kribben, A; Meuth, SG; Pfeuffer, S; Pfister, F; Pul, R; Ruck, T; Schönfelder, K; Schuh, H; Skuljec, J	1
Ethemoğlu, Ö; Seferoğlu, M; Siva, A; Turan, ÖF	1
Becker, V; Elias-Hamp, B; Grothe, C; Havla, J; Pul, R; Rau, D; Richter, S; Schmidt, S; Stangel, M	1
Comi, G; Dangond, F; Giovannoni, G; Jack, D; Keller, B; Rammohan, K; Rieckmann, P; Vermersch, P	1
Haham, N; Vaknin-Dembinsky, A	1
Al Malik, Y; Al-Johani, A; Al-Saqa'aby, M; Alarieh, R; Bohlega, S; Elboghdady, A; Mahajan, K; Mohamed, O; Mughari, MK	1
Afolabi, D; Albor, C; Altmann, DR; Baker, D; Schmierer, K; Zalewski, L	1
Barnett, M; Butler, E; Butzkueven, H; Duquette, P; Fabis-Pedrini, M; Ferraro, D; Girard, M; Grammond, P; Grand'Maison, F; Havrdova, E; Hodgkinson, S; Horakova, D; Hupperts, R; Jokubaitis, V; Kalincik, T; Kermode, A; Lechner-Scott, J; Lugaresi, A; McCombe, P; Prat, A; Prevost, J; Shaw, C; Slee, M; Sola, P; Solaro, C; Spelman, T; Terzi, M; Trojano, M	1
Holmøy, T; Myhr, KM; Torkildsen, Ø	1
Adeniji, AK; Comi, G; Cook, S; Dangond, F; Giovannoni, G; Rammohan, K; Rieckmann, P; Soelberg Sorensen, P; Vermersch, P	1
Akdemir, A; Çelik Turgut, G; Çetin, A; Dişli, A; Doyduk, D; Şen, A; Yavuz, S; Yıldırır, Y	1
Budhia, S; Harty, G; Hettle, R; Khurana, IS; Siddiqui, MK; Wong, SL	1
Giovannoni, G	1
Heesen, C; Riemann-Lorenz, K; Scheiderbauer, J; Schiffmann, I	1
De Stefano, N; Giorgio, A	1
Aktas, O; Hartung, HP; Meuth, SG; Ruck, T	1
Harty, G; Hettle, R; Wong, SL	1
Comi, G; Cook, S; Dangond, F; Giovannoni, G; Hicking, C; Rammohan, KW; Rieckmann, P; Soelberg Sorensen, P; Vermersch, P	1
Dangond, F; Hicking, C; Munafo, A; Terranova, N	1
Beale, S; Boland, A; Duarte, R; Greenhalgh, J; Kotas, E; Lambe, T; Mahon, J; McEntee, J; Nevitt, S; Pomeroy, I	1
Ramio-Torrenta, L; Robles-Cedeno, R	1
Grieb, P; Rejdak, K; Stelmasiak, Z	1
Baker, D; Herrod, SS; Pryce, G; Schmierer, K	1
Berardi, A; Harty, G; Siddiqui, MK; Treharne, C; Wong, SL	1
Alonso-Magdalena, L; Dangond, F; Galazka, A; Martinelli, V; Pfleger, C; Phillips, L; Rieckmann, P; Vermersch, P	1
Dangond, F; Friberg, LE; Hermann, R; Litwin, JS; Munafo, A	1
Comi, G; Cook, S; Galazka, A; Giovannoni, G; Hicking, C; Leist, T; Montalban, X; Nolting, A; Sylvester, E	1
Comi, G; Cook, S; Dangond, F; Galazka, A; Giovannoni, G; Hicking, C; Nolting, A; Rieckmann, P; Sørensen, PS; Vermersch, P	1
Polanco, A; Poveda, JL; Rubio-Rodríguez, D; Rubio-Terrés, C; Torres, C; Trillo, JL	1
Damian, D; Gorrod, HB; Harty, GT; Hettle, R; Latimer, NR; Wong, SL	1
Karlsson, MO; Krekels, EH; Munafo, A; Novakovic, AM; Ueckert, S	1
Battaglini, M; Dangond, F; De Leucio, A; De Stefano, N; Giorgio, A; Giovannoni, G; Hicking, C; Sormani, MP	1
Costello, K; Sipe, JC	1
Grieb, P; Jakubowska, B; Nowicki, J; Ryba, M; Solski, J; Stelmasiak, Z	1
Carroll, WM	1
Chang, P; Comi, G; Cook, S; Giovannoni, G; Greenberg, SJ; Hamlett, A; Musch, B; Rammohan, K; Rieckmann, P; Soelberg Sørensen, P; Vermersch, P	1
Bartosik-Psujek, H; Belniak, E; Mitosek-Szewczyk, K; Stelmasiak, Z	1
Sipe, JC	1
Yates, D	1
Havla, J; Hohlfeld, R; Kümpfel, T	1
Mann, H	1
Li, H; Zhang, X	1
Marriott, JJ; O'Connor, PW	1
Schmidt, S	1
Hartung, HP; Kieseier, BC; Stüve, O; Warnke, C; Wiendl, H	1
Comi, G; Cook, S; Giovannoni, G; Greenberg, SJ; Hamlett, A; Miret, M; Musch, B; Rammohan, K; Rieckmann, P; Sørensen, PS; Vermersch, P; Viglietta, V; Weiner, J	1
Muir, VJ; Plosker, GL	1
Cook, S; Giovannoni, G; Greenberg, S; Hamlett, A; Rammohan, K; Rieckmann, P; Sørensen, PS; Vermersch, P; Viglietta, V	1
Csépány, T	1
Hohlfeld, R	1
Killestein, J; Polman, CH; Rudick, RA	1
Ali, S; Comi, G; Cook, S; Giovannoni, G; Greenberg, S; Joyeux, A; Paracha, N; Rammohan, K; Rieckmann, P; Scott, DA; Sørensen, PS; Vermersch, P	1
Comi, G; Greenberg, SJ; Hartung, HP; Kurukulasuriya, NC; Scaramozza, M	1
Paul, F	1
Bartosik-Psujek, H; Belniak, E; Dobosz, B; Mitosek-Szewczyk, K; Stelmasiak, Z	1
Adams, HP; Feng, AC; Koziol, JA; Sobel, DF; Wagner, S	1
Cadavid, D; Cook, SD; Martinez-Rodriguez, JE; Pliner, L; Wolansky, LJ	1
Adams, H; Koziol, JA; Romine, JS; Sipe, JC; Slivka, LS; Sobel, DF; Wagner, S	1
Bartosik-Psujek, H; Belniak-Legieć, E; Mitosek-Szewczyk, K; Stelmasiak, Z	1
Bartosik-Psujek, H; Belniak-Legieć, E; Dobosz, B; Mitosek-Szewczyk, K; Stelmasiak, Z	1

Reviews

37 review(s) available for cladribine and Acute Relapsing Multiple Sclerosis

Article	Year
Safety and Monitoring of the Treatment with Disease-Modifying Therapies (DMTs) for Multiple Sclerosis (MS). Current reviews in clinical and experimental pharmacology, 2023, Volume: 18, Issue:1 Topics: Cladribine; Glatiramer Acetate; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab	2023
Real-world evidence for cladribine tablets in multiple sclerosis: further insights into efficacy and safety. Wiener medizinische Wochenschrift (1946), 2022, Volume: 172, Issue:15-16 Topics: Cladribine; COVID-19; COVID-19 Vaccines; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Nucleosides; SARS-CoV-2; Tablets	2022
Comparative safety of high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2022, Volume: 43, Issue:9 Topics: Adult; Alemtuzumab; Cladribine; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Network Meta-Analysis	2022
The effect of cladribine tablets in people with more active multiple sclerosis: a plain language summary. Neurodegenerative disease management, 2022, Volume: 12, Issue:6 Topics: Cladribine; Humans; Immunosuppressive Agents; Language; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Tablets	2022
Disease stability over five years in people with multiple sclerosis treated with cladribine tablets: a plain language summary. Neurodegenerative disease management, 2022, Volume: 12, Issue:6 Topics: Cladribine; Humans; Immunosuppressive Agents; Language; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Tablets	2022
Relapses in people with multiple sclerosis treated with cladribine tablets followed for up to 5 years: a plain language summary. Neurodegenerative disease management, 2022, Volume: 12, Issue:6 Topics: Cladribine; Humans; Immunosuppressive Agents; Language; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Tablets	2022
Systematic review and network meta-analysis (NMA) for cladribine tablets in achieving sustained disability improvement (SDI) in multiple sclerosis. Neurologia i neurochirurgia polska, 2022, Volume: 56, Issue:6 Topics: Bayes Theorem; Cladribine; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Network Meta-Analysis; Retrospective Studies; Tablets	2022
A plain language summary of the impact of vaccines against flu and chickenpox in people with multiple sclerosis treated with cladribine tablets. Neurodegenerative disease management, 2023, Volume: 13, Issue:1 Topics: Chickenpox; Cladribine; Herpesvirus 3, Human; Humans; Immunosuppressive Agents; Influenza Vaccines; Influenza, Human; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Tablets	2023
Cost, efficacy, and safety comparison between early intensive and escalating strategies for multiple sclerosis: A systematic review and meta-analysis. Multiple sclerosis and related disorders, 2023, Volume: 71 Topics: Adult; Cladribine; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab	2023
Safety and efficacy of cladribine in multiple sclerosis: a systematic review and meta-analysis. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2023, Volume: 44, Issue:9 Topics: Cladribine; Clinical Trials as Topic; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Observational Studies as Topic	2023
A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry. Neurodegenerative disease management, 2023, Volume: 13, Issue:4 Topics: Cladribine; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Registries; Tablets	2023
Long-term management of multiple sclerosis patients treated with cladribine tablets: an expert opinion. Expert opinion on pharmacotherapy, 2020, Volume: 21, Issue:16 Topics: Administration, Oral; Cladribine; Clinical Trials as Topic; Drug Administration Schedule; Drug Monitoring; Expert Testimony; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Practice Guidelines as Topic; Recurrence; Tablets; Treatment Outcome	2020
[Comparison of the clinical benefits of second-line drugs modifying the course of multiple sclerosis]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2020, Volume: 120, Issue:8 Topics: Cladribine; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting	2020
The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review. Drugs, 2020, Volume: 80, Issue:18 Topics: Chemistry, Pharmaceutical; Cladribine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Tablets	2020
Cladribine tablets versus other disease-modifying oral drugs in achieving no evidence of disease activity (NEDA) in multiple sclerosis-A systematic review and network meta-analysis. Multiple sclerosis and related disorders, 2021, Volume: 49 Topics: Cladribine; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Network Meta-Analysis; Tablets	2021
Efficacy classification of modern therapies in multiple sclerosis. Journal of comparative effectiveness research, 2021, Volume: 10, Issue:6 Topics: Cladribine; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Network Meta-Analysis; Recurrence	2021
[Disease-modifying treatment of secondary progressive multiple sclerosis]. Der Nervenarzt, 2021, Volume: 92, Issue:10 Topics: Cladribine; Disease Progression; Humans; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab	2021
The development and impact of cladribine on lymphoid and myeloid cells in multiple sclerosis. Multiple sclerosis and related disorders, 2021, Volume: 52 Topics: Cladribine; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Myeloid Cells	2021
Oral pulsed therapy of relapsing multiple sclerosis with cladribine tablets - expert opinion on issues in clinical practice. Multiple sclerosis and related disorders, 2021, Volume: 54 Topics: Cladribine; Expert Testimony; Female; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Neurologists; Pregnancy; Tablets	2021
An update on cladribine for relapsing-remitting multiple sclerosis. Expert opinion on pharmacotherapy, 2017, Volume: 18, Issue:15 Topics: Administration, Oral; Cladribine; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome	2017
Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis. Current medical research and opinion, 2018, Volume: 34, Issue:8 Topics: Alemtuzumab; Cladribine; Humans; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Network Meta-Analysis; Tablets	2018
Cladribine to Treat Relapsing Forms of Multiple Sclerosis. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2017, Volume: 14, Issue:4 Topics: Administration, Oral; Cladribine; Clinical Trials as Topic; Humans; Immunosuppressive Agents; Lymphocytes; Multiple Sclerosis, Relapsing-Remitting; Treatment Outcome	2017
[Cladribine tablets : Oral immunotherapy of relapsing-remitting multiple sclerosis with short yearly treatment periods]. Der Nervenarzt, 2018, Volume: 89, Issue:8 Topics: Administration, Oral; Cladribine; Humans; Immunosuppressive Agents; Immunotherapy; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Tablets	2018
Cladribine Tablets for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 2019, Volume: 37, Issue:3 Topics: Cladribine; Cost-Benefit Analysis; Humans; Immunosuppressive Agents; Models, Economic; Multiple Sclerosis, Relapsing-Remitting; Tablets; Technology Assessment, Biomedical	2019
[Cladribine in the treatment of relapsing multiple sclerosis]. Revista de neurologia, 2018, Nov-01, Volume: 67, Issue:9 Topics: Cladribine; Clinical Trials as Topic; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting	2018
Potential mechanisms of action related to the efficacy and safety of cladribine. Multiple sclerosis and related disorders, 2019, Volume: 30 Topics: Animals; Antigens, CD; Apoptosis; Central Nervous System; Cladribine; Humans; Immunosuppressive Agents; Lymphocytes; Multiple Sclerosis, Relapsing-Remitting	2019
Estimating the comparative efficacy of cladribine tablets versus alternative disease modifying treatments in active relapsing-remitting multiple sclerosis: adjusting for patient characteristics using meta-regression and matching-adjusted indirect treatmen Current medical research and opinion, 2019, Volume: 35, Issue:8 Topics: Cladribine; Disease Progression; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Tablets; Treatment Outcome	2019
Cladribine (Mavenclad) for multiple sclerosis. The Medical letter on drugs and therapeutics, 2019, Jul-29, Volume: 61, Issue:1577 Topics: Adult; Cladribine; Drug Costs; Female; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Pregnancy; Randomized Controlled Trials as Topic	2019
Cladribine tablets' potential in multiple: sclerosis treatment. The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses, 2008, Volume: 40, Issue:5 Topics: Administration, Oral; Cladribine; Drug-Related Side Effects and Adverse Reactions; Humans; Immunosuppressive Agents; Lymphocyte Depletion; Medication Adherence; Multiple Sclerosis, Relapsing-Remitting	2008
Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosis. Expert review of neurotherapeutics, 2010, Volume: 10, Issue:3 Topics: Administration, Oral; Cladribine; Clinical Trials, Phase III as Topic; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Product Surveillance, Postmarketing	2010
Emerging therapies in relapsing-remitting multiple sclerosis. Reviews on recent clinical trials, 2010, Volume: 5, Issue:3 Topics: Adjuvants, Immunologic; Administration, Oral; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Cladribine; Disease Progression; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; Treatment Outcome	2010
[Oral cladribine for relapsing-remitting multiple sclerosis: another purine analogue or a genuine therapeutic innovation?]. Der Nervenarzt, 2010, Volume: 81, Issue:10 Topics: Administration, Oral; Adverse Drug Reaction Reporting Systems; Animals; Azathioprine; Cladribine; Clinical Trials, Phase III as Topic; Disability Evaluation; Dose-Response Relationship, Drug; Female; Humans; Immunosuppressive Agents; Infusions, Intravenous; Long-Term Care; Lymphopenia; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Neoplasms; Pregnancy; Purine Nucleosides; Randomized Controlled Trials as Topic; Thrombocytopenia	2010
Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine. Drug design, development and therapy, 2010, Jul-21, Volume: 4 Topics: Administration, Oral; Animals; Cladribine; Clinical Trials as Topic; Drug Delivery Systems; Drug Design; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine	2010
Cladribine tablets: in relapsing-remitting multiple sclerosis. CNS drugs, 2011, Volume: 25, Issue:3 Topics: Administration, Oral; Animals; Cladribine; Clinical Trials as Topic; Disease Progression; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Tablets	2011
[Current treatment of multiple sclerosis]. Lege artis medicinae : uj magyar orvosi hirmondo, 2011, Volume: 21, Issue:2 Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cladribine; Dimethyl Fumarate; Drug Administration Schedule; Fingolimod Hydrochloride; Fumarates; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon-beta; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Peptides; Propylene Glycols; Quinolones; Sphingosine; Treatment Outcome	2011
Oral treatment for multiple sclerosis. The Lancet. Neurology, 2011, Volume: 10, Issue:11 Topics: Administration, Oral; Cladribine; Clinical Trials as Topic; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Propylene Glycols; Quinolones; Sphingosine; Toluidines	2011
Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis. Expert opinion on pharmacotherapy, 2013, Volume: 14, Issue:1 Topics: Administration, Oral; Cladribine; Clinical Trials, Phase III as Topic; Female; Humans; Immunosuppressive Agents; Lymphocytes; Male; Multiple Sclerosis, Relapsing-Remitting; Safety-Based Drug Withdrawals; Tablets	2013

Trials

23 trial(s) available for cladribine and Acute Relapsing Multiple Sclerosis

Article	Year
Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis. Multiple sclerosis and related disorders, 2022, Volume: 57 Topics: Adult; Cladribine; Female; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Neoplasm Recurrence, Local; Patient Satisfaction; Personal Satisfaction; Prospective Studies; Quality of Life; Tablets	2022
Prevalence of disability improvement in relapsing-remitting multiple sclerosis patients treated with cladribine tablets. European journal of neurology, 2022, Volume: 29, Issue:7 Topics: Cladribine; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Prevalence; Tablets	2022
Reduction in grey matter atrophy in patients with relapsing multiple sclerosis following treatment with cladribine tablets. European journal of neurology, 2023, Volume: 30, Issue:1 Topics: Atrophy; Brain; Cladribine; Disease Progression; Gray Matter; Humans; Magnetic Resonance Imaging; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Tablets	2023
Assessing the Long-Term Effectiveness of Cladribine vs. Placebo in the Relapsing-Remitting Multiple Sclerosis CLARITY Randomized Controlled Trial and CLARITY Extension Using Treatment Switching Adjustment Methods. Advances in therapy, 2020, Volume: 37, Issue:1 Topics: Adult; Algorithms; Cladribine; Disease Progression; Germany; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Placebo Effect; Tablets	2020
CLICK-MS and MASTER-2 Phase IV trial design: cladribine tablets in suboptimally controlled relapsing multiple sclerosis. Neurodegenerative disease management, 2021, Volume: 11, Issue:2 Topics: Administration, Oral; Cladribine; Female; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Prospective Studies; Quality of Life; Tablets	2021
Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2021, Volume: 18, Issue:2 Topics: Adolescent; Adult; Antibodies, Monoclonal, Humanized; Cladribine; Drug Substitution; Female; Follow-Up Studies; Humans; Immunologic Factors; Immunosuppressive Agents; Leukoencephalopathy, Progressive Multifocal; Male; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Prospective Studies; Retrospective Studies; Risk Factors; Rituximab; Young Adult	2021
Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres. Multiple sclerosis (Houndmills, Basingstoke, England), 2022, Volume: 28, Issue:2 Topics: Cladribine; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Prospective Studies	2022
Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies. Advances in therapy, 2021, Volume: 38, Issue:9 Topics: Cladribine; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Tablets	2021
Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. Multiple sclerosis (Houndmills, Basingstoke, England), 2018, Volume: 24, Issue:12 Topics: Adult; Cladribine; Double-Blind Method; Female; Humans; Immunosuppressive Agents; Longitudinal Studies; Lymphopenia; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Treatment Outcome	2018
Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study. Multiple sclerosis (Houndmills, Basingstoke, England), 2019, Volume: 25, Issue:6 Topics: Adult; Cladribine; Disease Progression; Female; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Outcome Assessment, Health Care; Severity of Illness Index	2019
Effects of Postponing Treatment in the Second Year of Cladribine Administration: Clinical Trial Simulation Analysis of Absolute Lymphocyte Counts and Relapse Rate in Patients with Relapsing-Remitting Multiple Sclerosis. Clinical pharmacokinetics, 2019, Volume: 58, Issue:3 Topics: Administration, Oral; Algorithms; Cladribine; Female; Humans; Immunosuppressive Agents; Lymphocyte Count; Lymphopenia; Male; Multiple Sclerosis, Relapsing-Remitting; Practice Guidelines as Topic; Recurrence; Time Factors; Time-to-Treatment	2019
Effects of cladribine tablets on heart rate, atrio-ventricular conduction and cardiac repolarization in patients with relapsing multiple sclerosis. British journal of clinical pharmacology, 2019, Volume: 85, Issue:7 Topics: Adult; Cladribine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heart Conduction System; Heart Rate; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Tablets	2019
Impact of Nonrandomized Dropout on Treatment Switching Adjustment in the Relapsing-Remitting Multiple Sclerosis CLARITY Trial and the CLARITY Extension Study. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2019, Volume: 22, Issue:7 Topics: Cladribine; Confounding Factors, Epidemiologic; Disability Evaluation; Disease Progression; Drug Substitution; Humans; Immunosuppressive Agents; Models, Statistical; Multiple Sclerosis, Relapsing-Remitting; Patient Dropouts; Time Factors; Treatment Outcome	2019
Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets. Multiple sclerosis (Houndmills, Basingstoke, England), 2018, Volume: 24, Issue:2 Topics: Adolescent; Adult; Aged; Atrophy; Brain; Cladribine; Disease Progression; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Outcome Assessment, Health Care; Risk; Young Adult	2018
Effect of parenteral cladribine on relapse rates in patients with relapsing forms of multiple sclerosis: results of a 2-year, double-blind, placebo-controlled, crossover study. Multiple sclerosis (Houndmills, Basingstoke, England), 2009, Volume: 15, Issue:6 Topics: Adult; Cladribine; Cross-Over Studies; Double-Blind Method; Female; Humans; Immunosuppressive Agents; Injections, Subcutaneous; Lymphocyte Count; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Placebos; Secondary Prevention; Treatment Outcome; Young Adult	2009
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. The New England journal of medicine, 2010, Feb-04, Volume: 362, Issue:5 Topics: Administration, Oral; Adolescent; Adult; Aged; Analysis of Variance; Brain; Cladribine; Disability Evaluation; Disease Progression; Double-Blind Method; Female; Herpes Zoster; Humans; Immunosuppressive Agents; Intention to Treat Analysis; Lymphopenia; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Young Adult	2010
Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study. Multiple sclerosis (Houndmills, Basingstoke, England), 2011, Volume: 17, Issue:5 Topics: Administration, Oral; Adult; Cladribine; Disability Evaluation; Double-Blind Method; Europe; Herpes Zoster; Humans; Immunosuppressive Agents; Lymphopenia; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Neoplasms; Neurologic Examination; Physical Examination; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; United States; Young Adult	2011
Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY Study. Clinical drug investigation, 2012, Jan-01, Volume: 32, Issue:1 Topics: Cladribine; Double-Blind Method; Health Care Rationing; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Placebos; Tablets	2012
Interleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis (RR-MS) treated with cladribine. Acta neurologica Scandinavica, 2004, Volume: 109, Issue:6 Topics: Adult; Chemokine CCL5; Cladribine; Female; Humans; Immunosuppressive Agents; Injections, Subcutaneous; Interleukin-8; Male; Multiple Sclerosis, Relapsing-Remitting	2004
Asymmetries in the spatial distributions of enhancing lesions and black holes in relapsing-remitting MS. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2005, Volume: 12, Issue:8 Topics: Adult; Brain; Cladribine; Double-Blind Method; Female; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Radiography	2005
New hypointense lesions on MRI in relapsing-remitting multiple sclerosis patients. European neurology, 2000, Volume: 43, Issue:4 Topics: Cladribine; Double-Blind Method; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Prognosis; Severity of Illness Index	2000
The effect of cladribine on some parameters of blood and cerebrospinal fluid in patients with relapsing-remitting multiple sclerosis (RR-MS). Annales Universitatis Mariae Curie-Sklodowska. Sectio D: Medicina, 2000, Volume: 55 Topics: Adult; Cerebrospinal Fluid Proteins; Cladribine; Female; Granulocytes; Humans; Injections, Subcutaneous; Kidney Function Tests; Leukocyte Count; Liver Function Tests; Lymphocyte Count; Male; Multiple Sclerosis, Relapsing-Remitting	2000
The levels of C3 and C4 components of the complement in the sera of relapsing-remitting multiple sclerosis patients (RR-MS) treated by 2-CDA (cladribine). Annales Universitatis Mariae Curie-Sklodowska. Sectio D: Medicina, 2000, Volume: 55 Topics: Adult; Autoimmune Diseases; Cladribine; Complement C3; Complement C4; Female; Humans; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting	2000

Other Studies

98 other study(ies) available for cladribine and Acute Relapsing Multiple Sclerosis

Article	Year
[Pharmacoeconomic aspects of using cladribine (in tablets) for treatment of adult patients with remitting multiple sclerosis]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2021, Volume: 121, Issue:8 Topics: Adult; Cladribine; Economics, Pharmaceutical; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Tablets	2021
Double immune reconstitution therapy: Cladribine after alemtuzumab in the treatment of multiple sclerosis. European journal of neurology, 2022, Volume: 29, Issue:3 Topics: Alemtuzumab; Cladribine; Humans; Immune Reconstitution; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting	2022
An Innovative Approach to Modelling the Optimal Treatment Sequence for Patients with Relapsing-Remitting Multiple Sclerosis: Implementation, Validation, and Impact of the Decision-Making Approach. Advances in therapy, 2022, Volume: 39, Issue:2 Topics: Cladribine; Cost-Benefit Analysis; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Quality of Life	2022
CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis. Multiple sclerosis and related disorders, 2022, Volume: 57 Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Cladribine; COVID-19; COVID-19 Vaccines; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; SARS-CoV-2; Vaccination	2022
Monitoring of safety and effectiveness of cladribine in multiple sclerosis patients over 50 years. Multiple sclerosis and related disorders, 2022, Volume: 58 Topics: Aged; Cladribine; Female; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Risk Assessment	2022
Disseminated nocardiosis after cladribine treatment for relapsing remitting multiple sclerosis: a case report. Journal of neurology, 2022, Volume: 269, Issue:8 Topics: Cladribine; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Nocardia Infections	2022
The CLARION study design and status update: a long-term, registry-based study evaluating adverse events of special interest in patients with relapsing multiple sclerosis newly started on cladribine tablets. Current medical research and opinion, 2022, Volume: 38, Issue:7 Topics: Cladribine; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Registries; Tablets	2022
Risk of fingolimod rebound after switching to cladribine or rituximab in multiple sclerosis. Multiple sclerosis and related disorders, 2022, Volume: 62 Topics: Cladribine; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Retrospective Studies; Rituximab	2022
Finnish multiple sclerosis patients treated with cladribine tablets: a nationwide registry study. Multiple sclerosis and related disorders, 2022, Volume: 61 Topics: Adult; Cladribine; Cohort Studies; Fingolimod Hydrochloride; Finland; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Registries; Tablets	2022
Impact of previous disease-modifying treatment on safety and efficacy in patients with MS treated with AHSCT. Journal of neurology, neurosurgery, and psychiatry, 2022, Volume: 93, Issue:8 Topics: Alemtuzumab; Cladribine; Hematopoietic Stem Cell Transplantation; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Rituximab; Transplantation, Autologous	2022
Predicting disease activity in patients with multiple sclerosis: An explainable machine-learning approach in the Mavenclad trials. CPT: pharmacometrics & systems pharmacology, 2022, Volume: 11, Issue:7 Topics: Cladribine; Humans; Immunosuppressive Agents; Machine Learning; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Young Adult	2022
The influence of disease-modifying therapy on hidden disability burden in people with newly diagnosed relapsing-remitting multiple sclerosis. Multiple sclerosis and related disorders, 2022, Volume: 63 Topics: Adult; Cladribine; Cohort Studies; Disabled Persons; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Motor Disorders; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting	2022
Confirmed disability progression as a marker of permanent disability in multiple sclerosis. European journal of neurology, 2022, Volume: 29, Issue:8 Topics: Cladribine; Cohort Studies; Disability Evaluation; Disease Progression; Female; Humans; Male; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Randomized Controlled Trials as Topic	2022
Longitudinal humoral response in MS patients treated with cladribine tablets after receiving the second and third doses of SARS-CoV-2 mRNA vaccine. Multiple sclerosis and related disorders, 2022, Volume: 63 Topics: Antibodies, Viral; Cladribine; COVID-19; COVID-19 Vaccines; Humans; Immunoglobulin G; Immunosuppressive Agents; mRNA Vaccines; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; SARS-CoV-2; Tablets; Vaccines, Synthetic	2022
Varicella zoster virus and influenza vaccine antibody titres in patients from MAGNIFY-MS who were treated with cladribine tablets for highly active relapsing multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England), 2022, Volume: 28, Issue:13 Topics: Cladribine; Herpesvirus 3, Human; Humans; Immunosuppressive Agents; Influenza Vaccines; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Tablets	2022
Immunological consequences of cladribine treatment in multiple sclerosis: A real-world study. Multiple sclerosis and related disorders, 2022, Volume: 64 Topics: CD8-Positive T-Lymphocytes; Cladribine; Humans; Immunosuppressive Agents; Lymphopenia; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Prospective Studies; Recurrence	2022
Prediction of relapse activity when switching to cladribine for multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England), 2023, Volume: 29, Issue:1 Topics: Chronic Disease; Cladribine; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence	2023
[Comments on the GLIMPSE study on evaluating the efficacy of the drug cladribine in tablets in routine clinical practice in comparison with other tablet drugs for the pathogenetic treatment of multiple sclerosis]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2022, Volume: 122, Issue:7. Vyp. 2 Topics: Cladribine; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Tablets	2022
Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4. Expert opinion on pharmacotherapy, 2022, Volume: 23, Issue:13 Topics: Cladribine; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Tablets	2022
Cytokine Secretion Dynamics of Isolated PBMC after Cladribine Exposure in RRMS Patients. International journal of molecular sciences, 2022, Sep-06, Volume: 23, Issue:18 Topics: Cladribine; Ficoll; Humans; Interleukin-17; Interleukin-4; Leukocytes, Mononuclear; Multiple Sclerosis, Relapsing-Remitting; Tumor Necrosis Factor-alpha	2022
Economic evaluation of cladribine tablets in high disease activity (HDA) relapsing multiple sclerosis (RMS) patients in Lebanon. Multiple sclerosis and related disorders, 2022, Volume: 67 Topics: Cladribine; Cost-Benefit Analysis; Humans; Immunosuppressive Agents; Lebanon; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Tablets	2022
Cladribine treatment for highly active multiple sclerosis: Real-world clinical outcomes for years 3 and 4. Journal of neuroimmunology, 2022, 11-15, Volume: 372 Topics: Adult; Cladribine; Female; Humans; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Retrospective Studies; Treatment Outcome	2022
Cladribine-induced liver injury: Implications for practice. Multiple sclerosis (Houndmills, Basingstoke, England), 2022, Volume: 28, Issue:13 Topics: Chemical and Drug Induced Liver Injury, Chronic; Cladribine; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting	2022
Fingolimod, teriflunomide and cladribine for the treatment of multiple sclerosis in women of childbearing age: description of drug utilization and exposed pregnancies in Germany. Multiple sclerosis and related disorders, 2022, Volume: 67 Topics: Child; Cladribine; Cross-Sectional Studies; Drug Utilization; Female; Fingolimod Hydrochloride; Germany; Humans; Immunosuppressive Agents; Infant, Newborn; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Pregnancy	2022
Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis. Journal of neurology, neurosurgery, and psychiatry, 2022, Volume: 93, Issue:12 Topics: Cladribine; Cohort Studies; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence; Treatment Outcome; Withholding Treatment	2022
Cladribine and pregnancy in women with multiple sclerosis: The first cohort study. Multiple sclerosis (Houndmills, Basingstoke, England), 2023, Volume: 29, Issue:3 Topics: Cladribine; Cohort Studies; Female; Humans; Immunosuppressive Agents; Infant, Newborn; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Pregnancy; Pregnancy Outcome; Recurrence	2023
Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry. Multiple sclerosis (Houndmills, Basingstoke, England), 2023, Volume: 29, Issue:2 Topics: Cladribine; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Registries; Retrospective Studies; Tablets	2023
High persistence and low adverse events burden in cladribine treated MS patients from Argentina. Multiple sclerosis and related disorders, 2022, Volume: 68 Topics: Adult; Argentina; Cladribine; Humans; Immunosuppressive Agents; Lymphopenia; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Tablets	2022
Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: A Danish nationwide study. Multiple sclerosis and related disorders, 2023, Volume: 70 Topics: Adult; Cladribine; Denmark; Female; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Tablets	2023
Cost-effectiveness of cladribine tablets and dimethyl fumarate in the treatment of relapsing remitting multiple sclerosis in Spain. Journal of comparative effectiveness research, 2023, Volume: 12, Issue:2 Topics: Cladribine; Cost-Benefit Analysis; Dimethyl Fumarate; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Spain	2023
Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study. Multiple sclerosis (Houndmills, Basingstoke, England), 2023, Volume: 29, Issue:6 Topics: Cladribine; Follow-Up Studies; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Neoplasm Recurrence, Local; Tablets	2023
Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing-remitting multiple sclerosis patients: a monocentric longitudinal observational study. Journal of neurology, 2023, Volume: 270, Issue:7 Topics: Cladribine; Drug-Related Side Effects and Adverse Reactions; Humans; Immunosuppressive Agents; Lymphopenia; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence	2023
Safety and effectiveness of cladribine tablets for multiple sclerosis: Results from a single-center real-world cohort. Multiple sclerosis and related disorders, 2023, Volume: 75 Topics: Adult; Cladribine; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Retrospective Studies; Tablets	2023
Revealing the immune cell subtype reconstitution profile in patients from the CLARITY study using deconvolution algorithms after cladribine tablets treatment. Scientific reports, 2023, 05-18, Volume: 13, Issue:1 Topics: Algorithms; CD8-Positive T-Lymphocytes; Cladribine; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Tablets	2023
Eyebrow alopecia associated with cladribine treatment for multiple sclerosis. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2023, Volume: 44, Issue:10 Topics: Alopecia; Cladribine; Eyebrows; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting	2023
Comparative effectiveness of cladribine tablets versus fingolimod in the treatment of highly active multiple sclerosis: A real-world study. Multiple sclerosis and related disorders, 2023, Volume: 76 Topics: Cladribine; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Retrospective Studies; Tablets	2023
A prospective observational longitudinal study with a two-year follow-up of multiple sclerosis patients on Cladribine. Clinical neurology and neurosurgery, 2023, Volume: 232 Topics: Adult; Cladribine; Contrast Media; Female; Follow-Up Studies; Gadolinium; Humans; Immunosuppressive Agents; Longitudinal Studies; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Prospective Studies	2023
Cladribine tablets for highly active relapsing-remitting multiple sclerosis in Poland: a real-world, multi-centre, retrospective, cohort study during the COVID-19 pandemic. Neurologia i neurochirurgia polska, 2023, Volume: 57, Issue:4 Topics: Adult; Cladribine; Cohort Studies; COVID-19; Humans; Immunosuppressive Agents; Lymphopenia; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Pandemics; Poland; Retrospective Studies; Tablets	2023
Transcriptome alterations in peripheral blood B cells of patients with multiple sclerosis receiving immune reconstitution therapy. Journal of neuroinflammation, 2023, Aug-02, Volume: 20, Issue:1 Topics: Alemtuzumab; Cladribine; Humans; Immune Reconstitution; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Neurodegenerative Diseases; RNA-Binding Proteins; Transcriptome; Ubiquitin-Protein Ligases	2023
Cladribine tablets in people with relapsing multiple sclerosis: A real-world multicentric study from southeast European MS centers. Journal of neuroimmunology, 2023, 09-15, Volume: 382 Topics: Cladribine; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Neoplasm Recurrence, Local; Retrospective Studies; Tablets	2023
[New neuroimaging methods in assessing the activity of neuroinflammation in multiple sclerosis]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2023, Volume: 123, Issue:7. Vyp. 2 Topics: Brain; Cladribine; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Neuroimaging; Neuroinflammatory Diseases; Tablets	2023
Evaluation of the use of high-efficacy treatments (HETs) in patients with relapsing-remitting multiple sclerosis in Argentina. Multiple sclerosis and related disorders, 2023, Volume: 79 Topics: Alemtuzumab; Argentina; Cladribine; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Retrospective Studies	2023
Real-world use of cladribine tablets (completion rates and treatment persistence) in patients with multiple sclerosis in England: The CLARENCE study. Multiple sclerosis and related disorders, 2023, Volume: 79 Topics: Cladribine; England; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Tablets	2023
Escalation Versus Induction/High-Efficacy Treatment Strategies for Relapsing Multiple Sclerosis: Which is Best for Patients? Drugs, 2023, Volume: 83, Issue:15 Topics: Alemtuzumab; Cladribine; Humans; Immunosuppressive Agents; Mitoxantrone; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab	2023
Evaluation of Patient-Reported Outcomes in Patients with Relapsing Multiple Sclerosis Treated with Cladribine Tablets in the CLAWIR Study: 12-Month Interim Analysis. Advances in therapy, 2023, Volume: 40, Issue:12 Topics: Adult; Cladribine; Female; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Patient Reported Outcome Measures; Prospective Studies; Tablets	2023
Real-world treatment patterns and effectiveness of cladribine tablets in patients with relapsing forms of multiple sclerosis in the United States. Multiple sclerosis and related disorders, 2023, Volume: 79 Topics: Adrenal Cortex Hormones; Adult; Cladribine; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Tablets; United States	2023
Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study. Multiple sclerosis (Houndmills, Basingstoke, England), 2023, Volume: 29, Issue:14 Topics: Cladribine; Humans; Immunosuppressive Agents; Lymphopenia; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Quality of Life; Tablets	2023
Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands. Applied health economics and health policy, 2019, Volume: 17, Issue:6 Topics: Adult; Cladribine; Cost-Benefit Analysis; Female; Humans; Immunosuppressive Agents; Male; Markov Chains; Multiple Sclerosis, Relapsing-Remitting; Netherlands; Quality-Adjusted Life Years	2019
Cost Assessment Modelling of Treatments for Highly Active Relapsing Multiple Sclerosis. Advances in therapy, 2020, Volume: 37, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Cladribine; Costs and Cost Analysis; Drug Costs; Female; Fingolimod Hydrochloride; Finland; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab	2020
Cost-effectiveness of cladribine tablets versus fingolimod in patients with highly active relapsing multiple sclerosis in Portugal. Journal of medical economics, 2020, Volume: 23, Issue:5 Topics: Adult; Age of Onset; Cladribine; Cost-Benefit Analysis; Disease Progression; Female; Fingolimod Hydrochloride; Health Expenditures; Health Resources; Humans; Immunosuppressive Agents; Male; Markov Chains; Middle Aged; Models, Economic; Multiple Sclerosis, Relapsing-Remitting; Portugal; Quality-Adjusted Life Years	2020
[Neurology 2019]. Revue medicale suisse, 2020, Jan-15, Volume: 16, Issue:676-7 Topics: Cladribine; Guillain-Barre Syndrome; Humans; Immunoglobulins, Intravenous; Multiple Sclerosis, Relapsing-Remitting; Neurology	2020
Severe fingolimod rebound syndrome after switching to cladribine treatment. Multiple sclerosis and related disorders, 2020, Volume: 40 Topics: Adult; Cladribine; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Recurrence	2020
Summarizing Patient Preferences for the Competitive Landscape of Multiple Sclerosis Treatment Options. Medical decision making : an international journal of the Society for Medical Decision Making, 2020, Volume: 40, Issue:2 Topics: Administration, Oral; Adolescent; Adult; Aged; Bayes Theorem; Cladribine; Decision Making; Europe; Female; Germany; Humans; Immunologic Factors; Immunosuppressive Agents; Injections; Interviews as Topic; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Netherlands; Patient Preference; United Kingdom; Young Adult	2020
Lichenoid rash: A new side effect of oral Cladribine. Multiple sclerosis and related disorders, 2020, Volume: 41 Topics: Adult; Cladribine; Exanthema; Humans; Immunosuppressive Agents; Lichenoid Eruptions; Male; Multiple Sclerosis, Relapsing-Remitting	2020
Remission of early persistent cladribine-induced neutropenia after filgrastim therapy in a patient with Relapsing - Remitting Multiple Sclerosis. Multiple sclerosis and related disorders, 2020, Volume: 43 Topics: Cladribine; Filgrastim; Humans; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Neutropenia; Recombinant Proteins	2020
Cladribine transfer into human milk: A case report. Multiple sclerosis (Houndmills, Basingstoke, England), 2021, Volume: 27, Issue:5 Topics: Breast Feeding; Cladribine; Female; Humans; Immunosuppressive Agents; Infant; Lactation; Milk, Human; Mothers; Multiple Sclerosis, Relapsing-Remitting	2021
Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy. Multiple sclerosis (Houndmills, Basingstoke, England), 2021, Volume: 27, Issue:3 Topics: Australia; Cladribine; Cohort Studies; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Registries	2021
Efficiency Model of Cladribine Tablets Versus Infusion-Based Disease-Modifying Drugs for Patients with Relapsing-Remitting Multiple Sclerosis. Advances in therapy, 2020, Volume: 37, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Cladribine; Female; Humans; Immunosuppressive Agents; Infusion Pumps; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Tablets; United Kingdom	2020
COVID-19 pneumonia in a multiple sclerosis patient with severe lymphopenia due to recent cladribine treatment. Multiple sclerosis (Houndmills, Basingstoke, England), 2020, Volume: 26, Issue:10 Topics: Betacoronavirus; Cladribine; Coronavirus Infections; COVID-19; Humans; Immunosuppressive Agents; Lymphopenia; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Pandemics; Pneumonia, Viral; SARS-CoV-2; Severity of Illness Index	2020
Cladribine vs other drugs in MS: Merging randomized trial with real-life data. Neurology(R) neuroimmunology & neuroinflammation, 2020, Volume: 7, Issue:6 Topics: Adult; Cladribine; Databases, Factual; Datasets as Topic; Disease Progression; Female; Humans; Immunologic Factors; Male; Middle Aged; Multicenter Studies as Topic; Multiple Sclerosis, Relapsing-Remitting; Observational Studies as Topic; Outcome Assessment, Health Care; Randomized Controlled Trials as Topic; Retrospective Studies; Severity of Illness Index	2020
Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice. Multiple sclerosis and related disorders, 2020, Volume: 45 Topics: Adult; Antibodies, Viral; Betacoronavirus; Cladribine; Coronavirus Infections; COVID-19; Female; Humans; Immunocompromised Host; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Pandemics; Pneumonia, Viral; SARS-CoV-2	2020
Severe disease activity in MS patients treated with cladribine after fingolimod withdrawal. Journal of the neurological sciences, 2020, 11-15, Volume: 418 Topics: Cladribine; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting	2020
COVID-19 in cladribine-treated relapsing-remitting multiple sclerosis patients: a monocentric experience. Journal of neurology, 2021, Volume: 268, Issue:8 Topics: Cladribine; COVID-19; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; SARS-CoV-2	2021
Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis. Multiple sclerosis and related disorders, 2020, Volume: 46 Topics: Cladribine; Europe; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Prospective Studies; Tablets	2020
Retinal cotton wool spot associated with cladribine therapy for multiple sclerosis. Multiple sclerosis and related disorders, 2021, Volume: 48 Topics: Cladribine; Humans; Immunosuppressive Agents; Lymphopenia; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting	2021
Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis: Current medical research and opinion, 2021, Volume: 37, Issue:3 Topics: Cladribine; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Tablets	2021
Immune phenotyping study revealing caveats regarding a switch from fingolimod to cladribine. Multiple sclerosis and related disorders, 2021, Volume: 48 Topics: Cladribine; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting	2021
A real-world single-centre analysis of alemtuzumab and cladribine for multiple sclerosis. Multiple sclerosis and related disorders, 2021, Volume: 52 Topics: Alemtuzumab; Cladribine; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Neoplasm Recurrence, Local; Retrospective Studies	2021
Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies. Multiple sclerosis (Houndmills, Basingstoke, England), 2022, Volume: 28, Issue:1 Topics: Cladribine; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Tablets	2022
How to switch disease-modifying treatments in multiple sclerosis: Guidelines from the French Multiple Sclerosis Society (SFSEP). Multiple sclerosis and related disorders, 2021, Volume: 53 Topics: Alemtuzumab; Cladribine; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab	2021
Autoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment. Multiple sclerosis (Houndmills, Basingstoke, England), 2021, Volume: 27, Issue:12 Topics: Cladribine; Glomerulonephritis; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Neoplasm Recurrence, Local	2021
MS and COVID-19 challenge: asymptomatic COVID-19 infection during treatment with cladribine. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2021, Volume: 42, Issue:9 Topics: Cladribine; COVID-19; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Pandemics; SARS-CoV-2	2021
COVID-19 in Cladribine-treated patient with multiple sclerosis. Journal of neuroimmunology, 2021, 10-15, Volume: 359 Topics: Cladribine; COVID-19; Drug Administration Schedule; Humans; Immunity, Humoral; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Treatment Outcome	2021
Economic Evaluation of Cladribine Tablets in Patients With High Disease Activity-Relapsing-Remitting Multiple Sclerosis in the Kingdom of Saudi Arabia. Value in health regional issues, 2021, Volume: 25 Topics: Cladribine; Cost-Benefit Analysis; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Saudi Arabia; Tablets	2021
Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England), 2018, Volume: 24, Issue:11 Topics: Adult; Cladribine; Clinical Trials, Phase III as Topic; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Quality of Life	2018
Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England), 2018, Volume: 24, Issue:12 Topics: Adult; Cladribine; Cohort Studies; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferon-beta; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propensity Score; Recurrence; Treatment Outcome	2018
Synthesis and Functional Investigations of Computer Designed Novel Cladribine-Like Compounds for the Treatment of Multiple Sclerosis. Archiv der Pharmazie, 2017, Volume: 350, Issue:11 Topics: Antineoplastic Agents; Apoptosis; B-Lymphocytes; Cell Cycle; Cell Line; Cladribine; Computer Simulation; DNA Breaks; DNA Damage; Humans; Immunosuppressive Agents; Molecular Docking Simulation; Multiple Sclerosis, Relapsing-Remitting; T-Lymphocytes	2017
Does cladribine have an impact on brain atrophy in people with relapsing remitting multiple sclerosis? Multiple sclerosis (Houndmills, Basingstoke, England), 2018, Volume: 24, Issue:10 Topics: Atrophy; Brain; Cladribine; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Tablets	2018
Response to 'Does cladribine have an impact on brain atrophy in people with relapsing remitting multiple sclerosis?' by Schiffmann et al. Multiple sclerosis (Houndmills, Basingstoke, England), 2018, Volume: 24, Issue:10 Topics: Atrophy; Brain; Cladribine; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting	2018
Cladribine for multiple sclerosis. Drug and therapeutics bulletin, 2018, Volume: 56, Issue:2 Topics: Administration, Oral; Adult; Cladribine; Contraindications, Drug; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting	2018
Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England. Journal of medical economics, 2018, Volume: 21, Issue:7 Topics: Adult; Alemtuzumab; Cladribine; Cost-Benefit Analysis; Disability Evaluation; Disease Progression; Female; Health Resources; Humans; Immunosuppressive Agents; Male; Markov Chains; Models, Econometric; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Quality-Adjusted Life Years; United Kingdom	2018
Cladribine induces long lasting oligoclonal bands disappearance in relapsing multiple sclerosis patients: 10-year observational study. Multiple sclerosis and related disorders, 2019, Volume: 27 Topics: Adult; Cladribine; Disease Progression; Female; Humans; Immunosuppressive Agents; Isoelectric Focusing; Male; Multiple Sclerosis, Relapsing-Remitting; Oligoclonal Bands; Prospective Studies; Treatment Outcome	2019
Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis. Clinical therapeutics, 2019, Volume: 41, Issue:2 Topics: Alemtuzumab; Cladribine; Crotonates; Decision Support Techniques; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Recurrence; Risk Assessment; Toluidines	2019
Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis. Multiple sclerosis and related disorders, 2019, Volume: 29 Topics: Adolescent; Adult; Aged; Cladribine; Clinical Trials, Phase III as Topic; Cohort Studies; Drug-Related Side Effects and Adverse Reactions; Female; Herpes Zoster; Humans; Immunosuppressive Agents; Lymphopenia; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Registries; Young Adult	2019
Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis. Multiple sclerosis and related disorders, 2019, Volume: 29 Topics: Adolescent; Adult; Aged; Cladribine; Clinical Trials, Phase III as Topic; Cohort Studies; Humans; Immunosuppressive Agents; Lymphocyte Count; Lymphocytes; Lymphopenia; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Outcome Assessment, Health Care; Randomized Controlled Trials as Topic; Registries; Tablets; Young Adult	2019
Cost-effectiveness of Cladribine Tablets and fingolimod in the treatment of relapsing multiple sclerosis with high disease activity in Spain. Expert review of pharmacoeconomics & outcomes research, 2020, Volume: 20, Issue:3 Topics: Adult; Cladribine; Cost-Benefit Analysis; Disability Evaluation; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Markov Chains; Multiple Sclerosis, Relapsing-Remitting; Quality-Adjusted Life Years; Spain	2020
Application of Item Response Theory to Modeling of Expanded Disability Status Scale in Multiple Sclerosis. The AAPS journal, 2017, Volume: 19, Issue:1 Topics: Cladribine; Clinical Trials, Phase III as Topic; Disability Evaluation; Disease Progression; Humans; Immunosuppressive Agents; Logistic Models; Models, Theoretical; Multiple Sclerosis, Relapsing-Remitting; Severity of Illness Index	2017
Promising outcomes from Phase III CLARITY study for the treatment of multiple sclerosis announced. Expert review of pharmacoeconomics & outcomes research, 2009, Volume: 9, Issue:3 Topics: Cladribine; Clinical Trials, Phase III as Topic; Disease Progression; Dose-Response Relationship, Drug; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Treatment Outcome	2009
Oral therapy for multiple sclerosis--sea change or incremental step? The New England journal of medicine, 2010, Feb-04, Volume: 362, Issue:5 Topics: Administration, Oral; Arrhythmias, Cardiac; Cladribine; Disease Progression; Female; Fingolimod Hydrochloride; Herpesviridae Infections; Humans; Immunosuppressive Agents; Interferon beta-1a; Interferon-beta; Male; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine	2010
Impact of cladribine on soluble adhesion molecules in multiple sclerosis. Acta neurologica Scandinavica, 2010, Volume: 122, Issue:6 Topics: Adult; Case-Control Studies; Cladribine; Disability Evaluation; E-Selectin; Enzyme-Linked Immunosorbent Assay; Female; Humans; Immunosuppressive Agents; Intercellular Adhesion Molecule-1; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Vascular Cell Adhesion Molecule-1; Young Adult	2010
Orally administered cladribine displays efficacy in multiplesclerosis trial. Nature reviews. Neurology, 2010, Volume: 6, Issue:4 Topics: Administration, Oral; Brain; Cladribine; Clinical Trials, Phase III as Topic; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Randomized Controlled Trials as Topic	2010
[Progress of therapy in patients with multiple sclerosis]. MMW Fortschritte der Medizin, 2010, Mar-04, Volume: 152, Issue:9 Topics: 4-Aminopyridine; Adrenal Cortex Hormones; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Brain; Cladribine; Clinical Trials as Topic; Fingolimod Hydrochloride; Magnetic Resonance Imaging; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propylene Glycols; Rituximab; Sphingosine	2010
Oral cladribine and fingolimod for relapsing multiple sclerosis. The New England journal of medicine, 2010, May-06, Volume: 362, Issue:18 Topics: Cladribine; Ethics, Research; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Informed Consent; Multiple Sclerosis, Relapsing-Remitting; Placebos; Propylene Glycols; Research Design; Sphingosine	2010
Oral cladribine and fingolimod for relapsing multiple sclerosis. The New England journal of medicine, 2010, May-06, Volume: 362, Issue:18 Topics: Administration, Oral; Cladribine; Disability Evaluation; Disease Progression; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting	2010
Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. The Lancet. Neurology, 2011, Volume: 10, Issue:4 Topics: Cladribine; Disease-Free Survival; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Odds Ratio; Randomized Controlled Trials as Topic; Treatment Outcome	2011
Multiple sclerosis: Cladribine--a contentious therapeutic contender for MS. Nature reviews. Neurology, 2011, Jul-12, Volume: 7, Issue:8 Topics: Cladribine; Clinical Trials as Topic; Device Approval; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine	2011
Cladribine in multiple sclerosis: pitfalls in a new treatment landscape. Expert opinion on pharmacotherapy, 2013, Volume: 14, Issue:1 Topics: Cladribine; Female; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis, Relapsing-Remitting	2013
Cladribine in aggressive forms of multiple sclerosis. European journal of neurology, 2007, Volume: 14, Issue:6 Topics: Adolescent; Adult; Cladribine; Disability Evaluation; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis, Relapsing-Remitting; Retrospective Studies	2007